Everything below concerns actin-binding fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
A new Constitution, introduced in 1984, re-enfranchised the Coloured population (women as well as men) and enfranchised the Indian population. It retained the existing House of Assembly for whites and established a House of Representatives to represent the Coloureds, and a House of Delegates for the Indians, making Parliament a tricameral legislature. Blacks continued to be excluded.
The current NIOSH definition for an IDLH condition, as given in the NIOSH Respirator Selection Logic, is one that poses a threat of exposure to airborne contaminants when that exposure is likely to cause death or immediate or delayed permanent adverse health effects or prevent escape from such an environment. The purpose of establishing an IDLH value is (1) to ensure that the worker can escape from a given contaminated environment in the event of failure of the respiratory protection equipment and (2) is considered a maximum level above which only a highly reliable breathing apparatus providing maximum worker protection is permitted. In September 1995, NIOSH issued a new policy for developing recommended exposure limits (RELs) for substances, including carcinogens. As benzene can cause cancer, NIOSH recommends that all workers wear special breathing equipment when they are likely to be exposed to benzene at levels exceeding the REL (10-hour) of 0.1 ppm. The NIOSH short-term exposure limit (STEL – 15 min) is 1 ppm. American Conference of Governmental Industrial Hygienists (ACGIH) adopted Threshold Limit Values (TLVs) for benzene at 0.02 ppm TWA in 2024. The European Union exposure limit value for benzene is 0.66 mg/m3. Germany's acceptable concentration (AC) is 0.2 mg/m3 and tolerable concentration (TC) is 1.9 mg/m3, where 1 mg/m3 is about 1 ppm in air.
Nonetheless, there have been sporadic reports of disturbances in the gastrointestinal flora of the infant, manifesting as diarrhea or oral candidiasis (thrush), associated with the use of β-lactam antibiotics, however, these potential side effects have not been thoroughly investigated specifically in the context of meropenem use, therefore, the safety profile of meropenem in breastfeeding mothers and their infants is unknown. Although meropenem is not approved for intramuscular or subcutaneous routes of administration in humans, there were studies that evaluated the drug bioavailability in cats and reported bioavailability of 99.69% for intramuscular route and 96.52 % for subcutaneous route of administration; these studies also compared elimination half-lives for intravenous, intramuscular or subcutaneous routes of administration in cats and reported duration of 1.35, 2.10 and 2.26 hours, respectively. There was also a small study on local tolerance of meropenem intramuscular administration in humans, and it was reported as generally good.
=== Vietnam War === U.S. soldiers during the Vietnam War era would sometimes use small amounts of C-4 as a fuel for heating rations, as it will burn unless detonated with a primary explosive. However, burning C-4 produces poisonous fumes, and soldiers are warned of the dangers of personal injury when using the plastic explosive. Among field troops in Vietnam a rumor circulated that ingestion of a small amount of C-4 would produce a "high" similar to alcohol. In fact, the RDX in C-4 is a strong vasodilator (cf. nitroglycerin), and its ingestion produces only unpleasant (e.g., migraine, fatigue, fever) or dangerous effects (e.g., severe kidney damage, seizures, coma). Due to this toxicity, some troops made use of the explosive to induce temporary illness in the hope of being sent on sick leave.
Sources: en.wikipedia.org
=== Other fronts === Mexico's participation in World War II was not exclusive to the 201st Squadron. Thousands of Mexicans fought on the battlefield as volunteers in foreign armies or as residents of other countries. There are figures of between 50 thousand to 80 thousand Mexicans who fought on different fronts, many of them did so voluntarily. On D-Day there were also Mexican fighters, all of whom were volunteers and born in other countries, including Luis Pérez Gómez (1922-1944), who enlisted as a pilot in the Royal Canadian Air Force, participating in various missions during the Normandy landings. One of the most prominent Mexicans as reinforcements for other troops was José M. López, who fought alongside the American troops and his bravery in the conflict was such that after the Allied victory, he was awarded the Medal of Honor, the highest decoration in the US Army. This after his participation in the Battle of the Bulge, where he and other soldiers counterattacked the German offensive. Mendoza, with a machine gun, left almost 100 casualties to the Germans.
== Epidemiology == Urbach–Wiethe disease is very rare; there are fewer than 300 reported cases in medical literature. Although Urbach–Wiethe disease can be found worldwide, almost a quarter of reported diagnoses are in South Africa. Many of these are in patients of Dutch, German, and Khoisan ancestry. This high frequency is thought to be due to the founder effect. Due to its recessive genetic cause and the ability to be a carrier of the disease without symptoms, Urbach–Wiethe disease often runs in families. In some regions of South Africa, up to one in 12 individuals may be carriers of the disease. Most of the case studies involving Urbach–Wiethe disease patients involve only one to three cases and these cases are often in the same family. Due to its low incidence, it is difficult to find a large enough number of cases to adequately study the disease.
=== NAADP-selective physiology === Hardly surprisingly, the three major second messengers do not do the same thing and cannot always substitute for each other. The physiological consequences of Ca2+ release by each messenger may be different i.e. NAADP couples to downstream responses that cannot be mimicked by IP3 and cADPR. For example, NAADP selectively stimulates neuronal differentiation, or exocytosis in cytotoxic T-cells.
== Early life == Hofmeister's father was a doctor in Prague, where Hofmeister first began his studies, under the physiologist Karl Hugo Huppert, himself a student of Carl Lehmann. Hofmeister's Habilitationsschrift in 1879 concerned the peptic products of digestion. Hofmeister became a Professor of Pharmacology at the First Faculty of Medicine, Charles University in Prague in 1885, then eventually moved to Strasbourg in 1896.
==== Buoyancy ==== Static liquids in uniform gravitational fields also exhibit the phenomenon of buoyancy, where objects immersed in the liquid experience a net force due to the pressure variation with depth. The magnitude of the force is equal to the weight of the liquid displaced by the object, and the direction of the force depends on the average density of the immersed object. If the density is smaller than that of the liquid, the buoyant force points upward and the object floats, whereas if the density is larger, the buoyant force points downward and the object sinks. This is known as Archimedes' principle.
Sources: en.wikipedia.org
The operation involved 150 aircraft from the United States Navy, Air Force, and Marine Corps. They included airplanes (Lockheed Martin F-22A Raptor, Lockheed Martin F-35A/C Lightning II, Boeing F/A-18E/F Super Hornet, Boeing EA-18G Growler, Grumman E-2D Hawkeye, Rockwell B-1B Lancer) and helicopters (Boeing MH-47G Chinooks and MH-60M DAP), refueling tankers, electronic-warfare (EW) planes, other support aircraft, and numerous unmanned aerial vehicles (including the Lockheed Martin RQ-170 Sentinel). Trump said the United States "had a fighter jet for every possible situation". Following the operation, White House press secretary Karoline Leavitt shared an eyewitness account of Venezuelan military personnel suffering injuries consistent with sonic weaponry during the American strike. Trump later told Katie Pavlich that "we have weapons nobody else knows about [...] we have some amazing weapons. That was an amazing attack." In a separate interview with the New York Post, he referred to one of these as a secret weapon called a "discombobulator," saying it caused Venezuelan defense systems, including Russian and Chinese rockets, to "not work," and that forces "pressed buttons and nothing worked." While Trump suggested the device disrupted equipment, CNN noted that reports of personnel injuries may have involved other technologies, such as acoustic or non-lethal systems such as the Active Denial System, rather than the classified weapon he described. The operation reportedly used one-way attack drones, which is believed to be the first such operational usage by the US military.
=== Emerging Applications === Recent developments have expanded the applications of organic molecular cages into new areas. Energy storage and conversion applications utilize cages as components in battery electrolytes and fuel cells. In environmental applications, cages demonstrate the potential for carbon capture and water purification through selective molecular binding. Biological applications represent another growing field. The biocompatibility of certain cage structures enables their use in drug delivery systems. Some cages can encapsulate and protect therapeutic molecules, releasing them under specific physiological conditions. Additionally, enzyme-mimetic cages catalyze biological transformations in artificial systems. Smart materials incorporating organic cages show stimuli-responsive behavior. These materials change properties in response to external stimuli such as light, temperature, or chemical signals. Applications include switchable membranes and responsive sensing systems.
=== European Union === In the EU, the European Medicines Agency issued a release recommending member states suspend marketing authorization for this product in the treatment of acute (not chronic) back pain. As of November 2007, carisoprodol has been taken off the market in Sweden due to problems with dependence and side effects. The agency overseeing pharmaceuticals considered other drugs used with the same indications as carisoprodol to have the same or better effects without the risks of the drug.
The Unitized Group Ration – A (UGR-A) is the successor to the A-ration, and consists of perishable entrées intended to be prepared in a field kitchen. The UGR-A is the only UGR with frozen food, and requires refrigeration to store and prepare. The UGR-A has 7 breakfast menus and 14 lunch/dinner menus. Each meal provides an average of 1,450 kcal. Each UGR-A module contains 50 meals, with each pallet holding 600 meals. UGR-A modules have a minimum shelf life of 9 months outside the contiguous U.S. and 3 months within the contiguous U.S., at 80 °F (26.6 °C) for semi-perishable modules and 0 °F (-17.7 °C) for perishable modules.
Use of this detection method is primarily found in the electrowetting of dielectric DMFs, where the sensing electrode apparatus can be reconfigurable and has a longer lifetime while still producing accurate results.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.